Related Experiment Video

Updated: Jun 1, 2026

Real-Time Monitoring of Aurora kinase A Activation using Conformational FRET Biosensors in Live Cells
06:29

Real-Time Monitoring of Aurora kinase A Activation using Conformational FRET Biosensors in Live Cells

Published on: July 30, 2020

Aurora kinase inhibitor patents and agents in clinical testing: an update (2009-10)

Chun Hei Antonio Cheung1, Mohane Selvaraj Coumar, Jang-Yang Chang

  • 1National Institute of Cancer Research, National Health Research Institutes, Tainan 70456, Taiwan, Republic of China.

Expert Opinion on Therapeutic Patents
|May 20, 2011
PubMed
Abstract

Insights

Aurora kinase inhibitors are promising cancer therapeutics. Combinations with chemotherapy show better outcomes than monotherapy, with many inhibitors in clinical trials.

Area of Science:

  • Cell Biology
  • Molecular Oncology
  • Medicinal Chemistry

Background:

  • Aurora kinases (A, B, C) regulate mitosis and are crucial for cell cycle progression.
  • Aberrant aurora kinase activity is linked to cancer development and chromosomal instability.
  • Small molecule inhibitors targeting aurora kinases are investigated as anti-cancer agents.

Purpose of the Study:

  • To review recent advancements in aurora kinase inhibitors from 2009-2010.
  • To focus on medicinal chemistry and patent literature for these inhibitors.
  • To provide an update on their therapeutic potential in cancer treatment.

Main Methods:

  • Literature review using PubMed, SCOPUS, Scifinder, and clinicaltrials.gov.
  • Analysis of medicinal chemistry aspects of aurora kinase inhibitors.
  • Emphasis on patent literature for inhibitor development.

Main Results:

  • Approximately twelve aurora kinase inhibitors are in Phase I-II clinical trials for various cancers.
  • Combination therapies of aurora kinase inhibitors with chemotherapy show improved results.
  • Ongoing research focuses on developing these inhibitors for cancer treatment.

Conclusions:

  • Aurora kinase inhibitors represent a promising targeted therapy for cancer.
  • Combination strategies are likely to enhance therapeutic efficacy.
  • Further clinical evaluations are underway for diverse human cancers.

More Related Videos

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries08:49

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays13:22

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Published on: October 23, 2019

Related Concept Videos

Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
Drug Administration and Therapy Phases: Overview01:26

Drug Administration and Therapy Phases: Overview

Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
FDA Approved Drugs: Changes to Approved Drugs01:26

FDA Approved Drugs: Changes to Approved Drugs

Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
Preclinical Development: Overview01:28

Preclinical Development: Overview

Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...